Prelude Therapeutics (PRLD)
NASDAQ:PRLD
US Market
Holding PRLD?
Track your performance easily

Prelude Therapeutics (PRLD) Financial Statements

123 Followers

Prelude Therapeutics Financial Overview

Prelude Therapeutics's market cap is currently ―. The company's EPS TTM is $-1.928; its P/E ratio is -0.67; Prelude Therapeutics is scheduled to report earnings on March 12, 2025, and the estimated EPS forecast is $-0.49. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Jun 23Mar 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -34.74M$ -34.34M$ -37.38M$ -30.43M$ -27.72M
EBITDA$ -32.35M$ -33.92M$ -37.05M$ -29.80M$ -27.45M
Net Income Common Stockholders$ -34.74M$ -31.43M$ -33.08M$ -30.43M$ -27.72M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 179.84M$ 201.92M$ 232.94M$ 254.99M$ 172.25M
Total Assets$ 224.29M$ 247.11M$ 277.67M$ 280.61M$ 198.32M
Total Debt$ 18.20M$ 17.64M$ 16.89M$ 938.00K$ 1.39M
Net Debt$ -161.64M$ -184.28M$ -216.05M$ -254.05M$ -170.87M
Total Liabilities$ 42.02M$ 36.37M$ 40.58M$ 18.55M$ 23.02M
Stockholders Equity$ 182.28M$ 210.73M$ 237.09M$ 262.06M$ 175.30M
Cash Flow-
Free Cash Flow$ -23.42M$ -32.08M$ -24.71M$ -59.59M$ -30.94M
Operating Cash Flow$ -23.06M$ -31.79M$ -23.58M$ -57.80M$ -30.13M
Investing Cash Flow$ 26.12M$ 31.22M$ 7.74M$ -57.43M$ 18.00M
Financing Cash Flow$ 59.00K$ -14.00K$ 25.24M$ 111.07M$ -269.00K
Currency in USD

Prelude Therapeutics Earnings and Revenue History

Prelude Therapeutics Debt to Assets

Prelude Therapeutics Cash Flow

Prelude Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis